Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590079 | 0.88 | S1PR1 (0.57) | S1PR1S1PR3RARBFFAR4FFAR1 | |
| SCHEMBL589158 | 0.84 | S1PR1 (0.40) | S1PR1S1PR3RARB | |
| SCHEMBL10168130 | 0.82 | S1PR1 (0.57) | S1PR1S1PR3RARBFFAR4FFAR1 | |
| SCHEMBL10168126 | 0.80 | S1PR1 (0.56) | S1PR1S1PR3FFAR4FFAR1 | |
| SCHEMBL6528237 | 0.77 | S1PR1 (0.57) | S1PR1S1PR3RARBFFAR4FFAR1 | |
| SCHEMBL588792 | 0.76 | S1PR1 (0.76) | S1PR1S1PR3 | |
| SCHEMBL590838 | 0.76 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL10168141 | 0.73 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL10168129 | 0.73 | S1PR1 (0.66) | S1PR1S1PR3RARBFFAR4FFAR1 | |
| SCHEMBL589925 | 0.73 | MEN1 (0.35) | S1PR1S1PR3FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | ADRB2, ADRB1, ADRB3 | S1PR1 843/4885S1PR3 583/4885RARB 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.